Triple-negative breast cancer: Early assessment with 18F-FDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse

Journal of Nuclear Medicine

Volumn 53, Issue 2, 2012, Pages 249-254

  Groheux, David ^a,b   Hindié, Elif ^a,b   Giacchetti, Sylvie ^a   Delord, Marc ^b   Hamy, Anne Sophie ^a   De Roquancourt, Anne ^a   Vercellino, Laetitia ^a   Berenger, Nathalie ^a   Marty, Michel ^a   Espié, Marc ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITÉ PARIS DIDEROT   (France)

Author keywords

18F FDG PET CT; Metabolic response; Neoadjuvant chemotherapy; Prognosis; Triple negative breast cancer

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; DRUG RESPONSE; FEMALE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; LYMPH NODE DISSECTION; MASTECTOMY; METABOLISM; MULTIPLE CYCLE TREATMENT; PARTIAL MASTECTOMY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGED; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; PATIENT SELECTION; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RECURRENCE; RISK; TIME FACTORS; TREATMENT OUTCOME;

EID: 84856806192     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.094045     Document Type: Article

References (20)

1. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938-1948.
2. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13:2329-2334. (Pubitemid 46698581)
3. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26:1275-1281.
4. 18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25:3746-3752.
5. Gallamini A, Patti C, Viviani S, et al. Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. Br J Haematol. 2011;152:551-560.
6. 18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol. 2006;24:5366-5372.
7. 18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2007;34:1915-1924.
8. 18F]fluorodeoxyglucose. J Clin Oncol. 2009;27:535-541.
9. 18F-FDG PET/CT: defining a clinical aim. Eur J Nucl Med Mol Imaging. 2011;38:419-425.
10. Lehmann-Che J, André F, Desmedt C, et al. Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers. Oncologist. 2010;15:246-252.
11. Gralow JR, Burstein HJ, Wood W, et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol. 2008;26:814-819. (Pubitemid 351265335)
12. Edge SB, Byrd DR, Compton CC, eds. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010.
13. Pierga J, Delaloge S, Espié M, et al. A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. Breast Cancer Res Treat. 2010;122:429-437.
14. Perez EA, Patel T, Moreno-Aspitia A. Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer. Breast Cancer Res Treat. 2010;121:261-271.
15. O'Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med. 2011;364:205-214.
16. Basu S, Chen W, Tchou J, et al. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer. 2008;112:995-1000. (Pubitemid 351304582)
17. 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011;38:426-435.
18. Specht JM, Kurland BF, Montgomery SK, et al. Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer. Clin Cancer Res. 2010;16:2803-2810.
19. Loo CE, Straver ME, Rodenhuis S, et al. Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. J Clin Oncol. 2011;29:660-666.
20. Kawashima H, Inokuchi M, Furukawa H, Kitamura S. Triple-negative breast cancer. Are the imaging findings different between responders and non-responders to neoadjuvant chemotherapy? Acad Radiol. 2011;18:963-969.